发明授权
US07115578B2 Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
失效
利巴韦林 - 干扰素α联合治疗用于根除慢性丙型肝炎感染患者可检测的HCV-RNA
- 专利标题： Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
- 专利标题（中）： 利巴韦林 - 干扰素α联合治疗用于根除慢性丙型肝炎感染患者可检测的HCV-RNA
-
申请号： US10885374申请日： 2004-07-06
-
公开(公告)号： US07115578B2公开(公告)日： 2006-10-03
- 发明人: Ashit K. Ganguly , Jinping McCormick , Raymond G. Lovey , Frank Bennett , Anil K. Saksena , Viyyoor M. Girijavallabhan
- 申请人： Ashit K. Ganguly , Jinping McCormick , Raymond G. Lovey , Frank Bennett , Anil K. Saksena , Viyyoor M. Girijavallabhan
- 申请人地址： US NJ Kenilworth
- 专利权人： Schering Corporation
- 当前专利权人： Schering Corporation
- 当前专利权人地址： US NJ Kenilworth
- 代理商 Melodie W. Henderson
- 主分类号： A01N43/04
- IPC分类号： A01N43/04 ; A61K31/70
摘要：
Ribavirin derivatives represented by the formula V, pharmaceutical compositions containing them as well as the use of the ribavirin derivatives represented by the formula V for the preparation of a medicament for the treatment of susceptible viral infections, for example, chronic hepatitis C infections administrating, the ribavirin derivatives being represented by formula V are disclosed.